Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.59 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 5/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29348994 | 0.87 | CNR2 (0.59) | CNR2CNR1PARP1 | |
| SCHEMBL31068267 | 0.87 | CNR2 (0.59) | CNR2CNR1PARP1 | |
| SCHEMBL31068290 | 0.74 | CNR2 (0.47) | CNR2CNR1KDM1A | |
| SCHEMBL29348996 | 0.74 | CNR2 (0.47) | CNR2CNR1KDM1A | |
| SCHEMBL31068116 | 0.74 | CNR2 (0.47) | CNR2CNR1 | |
| SCHEMBL29348644 | 0.74 | CNR2 (0.47) | CNR2CNR1 | |
| SCHEMBL29348285 | 0.72 | DDB1 (0.41) | CNR2 | |
| SCHEMBL31068362 | 0.71 | CNR2 (0.40) | CNR2ALOX5AP | |
| SCHEMBL29348585 | 0.71 | CNR2 (0.40) | CNR2ALOX5AP | |
| SCHEMBL31068179 | 0.71 | CNR2 (0.43) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |